JP2009525764A5 - - Google Patents

Download PDF

Info

Publication number
JP2009525764A5
JP2009525764A5 JP2008554523A JP2008554523A JP2009525764A5 JP 2009525764 A5 JP2009525764 A5 JP 2009525764A5 JP 2008554523 A JP2008554523 A JP 2008554523A JP 2008554523 A JP2008554523 A JP 2008554523A JP 2009525764 A5 JP2009525764 A5 JP 2009525764A5
Authority
JP
Japan
Prior art keywords
antibody
composition
cancer
fgf19
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008554523A
Other languages
English (en)
Japanese (ja)
Other versions
JP5209505B2 (ja
JP2009525764A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/061936 external-priority patent/WO2007136893A2/en
Publication of JP2009525764A publication Critical patent/JP2009525764A/ja
Publication of JP2009525764A5 publication Critical patent/JP2009525764A5/ja
Application granted granted Critical
Publication of JP5209505B2 publication Critical patent/JP5209505B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2008554523A 2006-02-10 2007-02-09 抗ｆｇｆ１９抗体およびその使用方法 Expired - Fee Related JP5209505B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US77231006P 2006-02-10 2006-02-10
US60/772,310 2006-02-10
US78060806P 2006-03-09 2006-03-09
US60/780,608 2006-03-09
US88586607P 2007-01-19 2007-01-19
US60/885,866 2007-01-19
PCT/US2007/061936 WO2007136893A2 (en) 2006-02-10 2007-02-09 Anti-fgf19 antibodies and methods using same

Publications (3)

Publication Number Publication Date
JP2009525764A JP2009525764A (ja) 2009-07-16
JP2009525764A5 true JP2009525764A5 (enExample) 2010-03-18
JP5209505B2 JP5209505B2 (ja) 2013-06-12

Family

ID=38723925

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008554523A Expired - Fee Related JP5209505B2 (ja) 2006-02-10 2007-02-09 抗ｆｇｆ１９抗体およびその使用方法

Country Status (10)

Country Link
US (4) US7678373B2 (enExample)
EP (1) EP1989230B1 (enExample)
JP (1) JP5209505B2 (enExample)
AR (1) AR059432A1 (enExample)
AU (1) AU2007254005B2 (enExample)
CA (1) CA2637988A1 (enExample)
ES (1) ES2582652T3 (enExample)
NZ (1) NZ569957A (enExample)
TW (1) TWI388568B (enExample)
WO (1) WO2007136893A2 (enExample)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
DE10254601A1 (de) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
EP2083081A1 (en) 2005-07-22 2009-07-29 Five Prime Therapeutics, Inc. Compositions and methods of treating disease with FGFR fusion proteins
CA2637988A1 (en) * 2006-02-10 2007-11-29 Genentech, Inc. Anti-fgf19 antibodies and methods using same
US20100267145A1 (en) * 2006-06-05 2010-10-21 Hiroshima University Immunocompetent cell having anti-cd38 antibody on its cell surface
EP1918376A1 (en) * 2006-11-03 2008-05-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. FGFR4 promotes cancer cell resistance in response to chemotherapeutic drugs
RS57149B1 (sr) * 2007-04-02 2018-07-31 Genentech Inc Kloto-beta agonist antitelo za primenu u tretmanu dijabetes melitusa ili otpornosti na insulin
CA2693852C (en) * 2007-08-03 2016-11-29 Genentech, Inc. Humanized anti-fgf19 antagonists and methods using same
US20090309617A1 (en) * 2007-08-24 2009-12-17 Ye Fang Biosensor antibody functional mapping
US20090226459A1 (en) * 2008-01-29 2009-09-10 Cold Spring Harbor Laboratory Role of fgf-19 in cancer diagnosis and treatment
AU2009243233A1 (en) * 2008-04-30 2009-11-05 Wntresearch Ab Restoration of estrogen receptor-alpha activity
KR20110028450A (ko) 2008-06-16 2011-03-18 이뮤노젠 아이엔씨 새로운 상승 효과
FR2933702A1 (fr) * 2008-07-08 2010-01-15 Sanofi Aventis Antagonistes specifiques du recepteur fgf-r4
WO2010006214A1 (en) * 2008-07-09 2010-01-14 Ambrx, Inc. Fgf-21 neutralizing antibodies and their uses
BRPI0916904A2 (pt) 2008-08-04 2016-10-11 Fiveprime Therapeutics Inc polipeptídeos, moléculares de fusão ecd fgfr4, composições farmacêuticas, polinucleotídio e métodos de tratamento de desordem angiogênica, câncer em paciente e degeneração macular em paciente e respectivos usos
US20100136584A1 (en) * 2008-09-22 2010-06-03 Icb International, Inc. Methods for using antibodies and analogs thereof
US20100092470A1 (en) * 2008-09-22 2010-04-15 Icb International, Inc. Antibodies, analogs and uses thereof
WO2011034940A1 (en) 2009-09-15 2011-03-24 Five Prime Therapeutics, Inc. Hair growth methods using fgfr4 extracellular domains
JP6016636B2 (ja) * 2009-10-15 2016-10-26 ジェネンテック， インコーポレイテッド 改変したレセプター特異性を持つキメラ線維芽細胞増殖因子
LT2498799T (lt) 2009-11-13 2016-11-10 Five Prime Therapeutics, Inc. Fgfr1 ekstraląstelinio domeno baltymų panaudojimas gydymui vėžio su nuo ligando priklausančiomis, aktyvuojančiomis fgfr2 mutacijomis
MX2012006406A (es) 2009-12-04 2012-07-25 Genentech Inc Anticuerpos multiespecificos, analogos de anticuerpo, composiciones y metodos.
WO2011084711A2 (en) 2009-12-17 2011-07-14 Five Prime Therapeutics, Inc. Hair growth methods using fgfr3 extracellular domains
JP4881428B2 (ja) * 2009-12-25 2012-02-22 株式会社東芝 電子機器
US8481038B2 (en) 2010-11-15 2013-07-09 Five Prime Therapeutics, Inc. Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins
US8951972B2 (en) 2010-12-09 2015-02-10 Five Prime Therapeutics, Inc. FGFR1 extracellular domain combination therapies for lung cancer
DK2683736T3 (en) 2011-03-09 2018-04-23 Cell Signaling Technology Inc METHODS AND REAGENTS FOR CREATING MONOCLONAL ANTIBODIES
EP2723391B1 (en) * 2011-06-24 2018-06-13 University of Miami Fibroblast growth factor receptor inhibition for the treatment of disease
HK1202240A1 (en) 2011-11-14 2015-09-25 戊瑞治疗有限公司 Methods of treating cancer
US10112988B2 (en) 2012-01-09 2018-10-30 Icb International, Inc. Methods of assessing amyloid-beta peptides in the central nervous system by blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an anti-amyloid-beta peptide
US10112987B2 (en) 2012-01-09 2018-10-30 Icb International, Inc. Blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an amyloid-beta peptide
JP2015506944A (ja) * 2012-01-18 2015-03-05 ジェネンテック， インコーポレイテッド Ｆｇｆ１９修飾薬を使用する方法
WO2013167153A1 (en) * 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Antibodies useful in cancer diagnosis
EP2872534B1 (en) 2012-07-13 2018-08-08 Roche Glycart AG Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
NZ746691A (en) 2012-11-13 2020-08-28 Astellas Pharma Inc Agents for treatment of claudin expressing cancer diseases
PE20160546A1 (es) 2013-10-25 2016-05-26 Novartis Ag Compuestos derivados de piridilo biciclicos fusionados a anillo como inhibidores de fgfr4
JP6673847B2 (ja) * 2013-12-20 2020-03-25 アンギオビオメト ゲゼルシャフト ミット ベシュレンクテル ハフツング 癌治療に使用するためのアドレノメデュリンバインダー
TWI728373B (zh) 2013-12-23 2021-05-21 美商建南德克公司 抗體及使用方法
JP6585167B2 (ja) 2014-10-03 2019-10-02 ノバルティス アーゲー Ｆｇｆｒ４阻害剤としての縮環二環式ピリジル誘導体の使用
CN114129709A (zh) * 2014-10-23 2022-03-04 恩格姆生物制药公司 包含肽变异体的药物组合物及其使用方法
US10189813B2 (en) 2015-03-25 2019-01-29 Novartis Ag Formylated N-heterocyclic derivatives as FGFR4 inhibitors
US10995143B2 (en) 2016-02-10 2021-05-04 Daiichi Sankyo Europe Gmbh Combination of human anti-FGFR4 antibody and Sorafenib
JP6911019B2 (ja) * 2016-05-17 2021-07-28 公益財団法人がん研究会 Ｅｇｆｒ−ｔｋｉ耐性を獲得した肺癌の治療薬
WO2018055503A1 (en) 2016-09-20 2018-03-29 Novartis Ag Combination comprising a pd-1 antagonist and an fgfr4 inhibitor
KR102362648B1 (ko) 2016-11-02 2022-02-11 노파르티스 아게 Fgfr4 억제제 및 담즙산 격리제의 조합물
US20190218285A1 (en) * 2018-01-18 2019-07-18 Molecular Cloning Laboratories (MCLAB) LLC Long-Acting Therapeutic Fusion Proteins
CN109251983B (zh) * 2018-08-15 2022-03-25 深圳市罗湖区人民医院 Frs2基因的拷贝数扩增及其应用、检测拷贝数扩增的特异性引物对
KR102467349B1 (ko) 2018-10-29 2022-11-16 에프. 호프만-라 로슈 아게 항체 제형
JP7643727B2 (ja) * 2019-02-02 2025-03-11 華輝安健(北京)生物科技有限公司 抗－ｆｇｆ１９抗体
PL3865155T3 (pl) * 2020-02-13 2023-01-30 Orano Med Sposób miejscowo-specyficznego modyfikowania przeciwciała
CN116726005B (zh) * 2022-03-03 2026-02-13 上海市第六人民医院 一种治疗运动损伤的药物及筛选方法和应用
KR20250012564A (ko) 2022-05-19 2025-01-24 타이라 바이오사이언시스, 인크. Ppar 효현제 및 fgfr4 저해제를 이용한 치료법
EP4509142A1 (en) 2023-08-16 2025-02-19 Ona Therapeutics S.L. Fgfr4 as target in cancer treatment

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US20020042367A1 (en) * 1997-11-25 2002-04-11 Genentech, Inc. Fibroblast growth factor-19 (FGF-19) nucleic acids and polypeptides and methods of use for the treatment of obesity and related disorders
US20020012961A1 (en) * 1999-04-15 2002-01-31 Genentech, Inc. Fibroblast growth factor- 19
US20020155543A1 (en) * 1997-11-25 2002-10-24 Genentech, Inc. Fibroblast growth factor-19 (FGF-19) nucleic acids and polypeptides and methods of use for the treatment of obesity and related disorders
KR100506786B1 (ko) 1997-11-25 2005-08-08 제넨테크, 인크. 섬유아세포 성장인자-19
US20040126852A1 (en) * 1997-11-25 2004-07-01 Genentech, Inc. Fibroblast growth factor-19 (FGF-19) nucleic acids and polypeptides and methods of use for the treatment of obesity
US20050026832A1 (en) * 1997-11-25 2005-02-03 Genentech, Inc. Fibroblast growth factor-19 (FGF-19) nucleic acids and polypeptides and methods of use for the treatment of obesity and related disorders
US7459540B1 (en) 1999-09-07 2008-12-02 Amgen Inc. Fibroblast growth factor-like polypeptides
ES2264929T3 (es) 1999-09-08 2007-02-01 Genentech, Inc. Acidos nucleicos y polipeptidos del factor 19 de crecimiento fibroblastico (fgf-19) y procedimientos de utilizacion para el tratamiento de la obesidad.
EP1268793A2 (en) 2000-03-22 2003-01-02 Amgen, Inc. Fibroblast growth factor receptor-like molecules and uses thereof
AU2002234799A1 (en) 2000-12-08 2002-06-18 Ipsogen Gene expression profiling of primary breast carcinomas using arrays of candidate genes
WO2003025138A2 (en) 2001-09-17 2003-03-27 Protein Design Labs, Inc. Methods of diagnosis of cancer compositions and methods of screening for modulators of cancer
AU2003225535A1 (en) 2002-01-31 2003-09-02 Millennium Pharmaceuticals, Inc. Methods and compositions for treating cancer
AU2003243400B2 (en) * 2002-06-07 2009-10-29 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US20050198642A1 (en) * 2004-03-04 2005-09-08 International Business Machines Corporation Mechanism for assigning home nodes to newly created threads
US7837626B2 (en) * 2005-08-05 2010-11-23 Siemens Medical Solutions Usa, Inc. Contrast agent manipulation with medical ultrasound imaging
CA2637988A1 (en) * 2006-02-10 2007-11-29 Genentech, Inc. Anti-fgf19 antibodies and methods using same

Similar Documents

Publication Publication Date Title
JP2009525764A5 (enExample)
TWI769537B (zh) 標靶ｂｃｍａ的抗體、雙專一性抗體及其用途
JP2010531140A5 (enExample)
JP2017529838A5 (enExample)
JP2020517249A5 (enExample)
JP2010532982A5 (enExample)
JP2010509931A5 (enExample)
JPWO2019129221A5 (enExample)
JP2018519364A5 (enExample)
HRP20140244T1 (hr) Sastavi i metode za inhibiranje pdgfrbeta i vegf-a
JP2009545325A5 (enExample)
HRP20131107T1 (hr) Anti-notch1 nrr-protutijela i postupak njihove uporabe
JP2017522861A5 (enExample)
JP2008529489A5 (enExample)
JP2013538553A5 (enExample)
JP2017514461A5 (enExample)
JP2008500815A5 (enExample)
RU2013102225A (ru) АНТИТЕЛА ПРОТИВ Axl И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
JP2011514150A5 (enExample)
JP2015517300A5 (enExample)
JP2010526028A5 (enExample)
HRP20110187T1 (hr) Multispecifične deimunizirane tvari koje vežu cd3
WO2011103700A1 (zh) 一种全人源抗her2单克隆抗体、其制备方法及用途
JP2011207882A5 (enExample)
JP2010520290A5 (enExample)